Skip to main content

Advertisement

Table 4 Plasma lipid changes induced by supplementary treatment with BBR/P/RR in 30 HeFH patients on stable-dose therapy with STs or STs plus EZE

From: Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

Lipid parameter Baseline on STs or STs + EZE % changes vs baseline plus BBR/P/RR % changes after BBR/P/RR addition P
TC (mmol/L) 9.94 ± 1.49 6.35 ± 0.99 −35.5 ± 8.5 5.54 ± 0.77†‡ −43.7 ± 7.3 < 0.001
LDL-C (mmol/L) 7.91 ± 1.35 4.47 ± 0.94 −42.6 ± 10.9 3.65 ± 0.71†§ −53.2 ± 8.7 < 0.001
HDL-C (mmol/L) 1.29 ± 0.39 1.30 ± 0.35 +2.6 ± 10.3 1.33 ± 0.38 +4.3 ± 11.4 NS
non-HDL-C (mmol/L) 8.65 ± 1.47 5.05 ± 1.06 −41.2 ± 9.8 4.20 ± 0.84†‡ −50.9 ± 8.7 < 0.001
TG (mmol/L) 1.48 (0.98-2.30) 1.27 (0.89-2.03) −17.7 ± 17.2 1.11 (0.83-1.63)* −23.1 ± 21.2 < 0.03
  1. Values are means ± SD or medians (interquartile ranges). *P <0.05 vs baseline, P < 0.02 vs baseline; P < 0.05 vs STs and STs + EZE, §P < 0.02 vs STs and STs + EZE (ANOVA and multiple comparisons among pairs of means by t-tests with Bonferroni's correction). P: significance of the differences between percent changes induced by STs or STs + EZE and those induced by treatment supplementation with BBR/P/RR (Student’s t test for paired data or Wilcoxon test). NS: not significant.